Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 6/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 0.67 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21378627 | 0.90 | TTR (0.81) | TTRALBP2RX7MEN1KMT2A | |
| SCHEMBL22132086 | 0.85 | TTR (0.73) | TTRALBCYP4F2CYP4A11 | |
| Acoramidis SCHEMBL29350324 | 0.80 | TTR (1.00) | TTRALBMEN1KMT2A | |
| Acoramidis SCHEMBL15816954 | 0.80 | TTR (1.00) | TTRALBMEN1KMT2A | |
| Acoramidis SCHEMBL20475239 | 0.79 | TTR (0.98) | TTRALBMEN1KMT2A | |
| Acoramidis SCHEMBL29390976 | 0.79 | TTR (0.98) | TTRALBMEN1KMT2A | |
| SCHEMBL15832081 | 0.78 | TTR (0.95) | TTRALBMEN1KMT2A | |
| SCHEMBL15820541 | 0.73 | TTR (0.65) | TTRALBPOLBNPC1RAB9A | |
| SCHEMBL13535958 | 0.73 | TTR (0.57) | TTRALBPOLBCASP6RAB9A | |
| SCHEMBL26740155 | 0.73 | TTR (0.65) | TTRALBCYP4F2CYP4A11POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041276-A1 | METHODS OF TREATING TTR AMYLOIDOSIS USING AG10 | ALTER DOMUS (US) LLC, AS COLLATERAL AGENT | 2025-02-06 | — | — | US | disclosed |
| US-12070449-B2 | Methods of treating TTR amyloidosis using AG10 | Eidos Therapeutics, Inc. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20220184041-A1 | (AZA)Benzothiazolyl Substituted Pyrazole Compounds | PFIZER INC. (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220016081-A1 | METHODS OF TREATING TTR AMYLOIDOSIS USING AG10 | ADRENAS THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-11058668-B2 | Methods of treating TTR amyloidosis using AG10 | Eidos Therapeutics, Inc. (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3768841-A1 | METHODS OF TREATING TTR AMYLOIDOSIS USING AG10 | Eidos Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| CN-112218632-A | Methods of treating TTR amyloidosis with AG10 | 文涵治疗有限公司 | 2021-01-12 | — | — | CN | disclosed |
| WO-2019183463-A1 | METHODS OF TREATING TTR AMYLOIDOSIS USING AG10 | Eidos Therapeutics, Inc. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20190290616-A1 | METHODS OF TREATING TTR AMYLOIDOSIS USING AG10 | QED THERAPEUTICS, INC. | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290616-A1 | METHODS OF TREATING TTR AMYLOIDOSIS USING AG10 | TTR, TMSB10, APOB | TTR 1/4885ALB 4/4885P2RX7 4516/4885 |
| US-20250041276-A1 | METHODS OF TREATING TTR AMYLOIDOSIS USING AG10 | TTR, TMSB10, APOB | TTR 1/4885ALB 4/4885P2RX7 4516/4885 |
| US-12070449-B2 | Methods of treating TTR amyloidosis using AG10 | TTR, APOB, TMSB10 | TTR 1/4885ALB 4/4885P2RX7 4514/4885 |
| US-20220016081-A1 | METHODS OF TREATING TTR AMYLOIDOSIS USING AG10 | TTR, APOB, TMSB10 | TTR 1/4885ALB 4/4885P2RX7 4514/4885 |
| US-11058668-B2 | Methods of treating TTR amyloidosis using AG10 | TTR, TMSB10, APOB | TTR 1/4885ALB 4/4885P2RX7 4516/4885 |
| US-20220184041-A1 | (AZA)Benzothiazolyl Substituted Pyrazole Compounds | TTR, APOB, SERPINB6 | TTR 1/4885ALB 6/4885P2RX7 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.